A Randomized, Open-label, Single Dose, Cross-over Clinical Trial to Compare the Safety, Tolerability, and Pharmacokinetic Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216 in Healthy Adult Subjects
Latest Information Update: 27 Sep 2022
At a glance
- Drugs DA 5216 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Dong-A ST
- 21 Sep 2022 Status changed from not yet recruiting to recruiting.
- 26 Aug 2022 New trial record